Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Non-covalent carriage of anticancer agents by humanized antibody trastuzumab.

Journal of molecular modeling - 1 May 2016

Yadav Arpita, Sharma Sweta, Yadav Veejendra Kumar

Abstract excerpt

This article explores the internalization and non-covalent carriage of small molecule anticancer agents like vinca alkaloids by humanized monoclonal antibody trastuzumab. Such carriage is marked by significant reduction in side effects and increased therapeutic value of these anticancer agents. This study is coherent with few clinical observations of enhanced efficiency of these anticancer agents when...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Carriers
Share to Immunoglobulin Fab Fragments
Share to Molecular Docking Simulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Static Electricity

Share to Trastuzumab

Share to Vinblastine

Share to Vincristine

Share to Vinorelbine

Source

Identifiers

PMID: 27109707
DOI: 10.1007/s00894-016-2986-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Non-covalent carriage of anticancer agents by humanized antibody trastuzumab.PMID 27109707Read ↗

A general approach to reduce off-target radioactivity in vivo via Tetrazine-Knock-Out (TKO)Semantic proximity Read ↗

Nab-paclitaxel fused with the <i>de novo</i> designed receptor binder exhibits enhanced tumor targeting and therapeutic efficacySemantic proximity Read ↗

Antibody and antibody fragments Site Specific Conjugation using New Q-tag Substrate of Bacterial Transglutaminase.Semantic proximity Read ↗

Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silicobased mechanismSemantic proximity Read ↗

In vitro affinity maturation to improve the efficacy of a hypoxia-inducible factor 1α single-domain intrabody.Semantic proximity Read ↗

Application of proteometric approach for identification of functional mutant sites to improve the binding affinity of anticancer biologic trastuzumab with its antigen human epidermal growth factor receptor 2.Semantic proximity Read ↗

Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumabSemantic proximity Read ↗

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugsSemantic proximity Read ↗

Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation.Semantic proximity Read ↗

Development and Validation Molecular Docking Analysis of Human serum albumin (HSA)Semantic proximity Read ↗

A recombinant fragment antigen-binding (Fab) of trastuzumab displays low cytotoxic profile in adult human cardiomyocytes: first evidence and the key implication of FcγRIIA receptorSemantic proximity Read ↗

An anti-EGFR × cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.